** Shares of healthcare products distributor Henry Schein HSIC.O rise ~4% to $71.94
** BofA Securities upgrades stock to "buy" from "underperform"; raises price objective to $84 from $69
** HSIC stands out as a "best-of-breed dental asset" with a proven ability to grow earnings at healthy rates, similar to its performance before COVID-19, brokerage says
** Company is well-positioned to gain share from both distributors and manufacturers due to its exposure to high-growth dental service organizations (DSO) customers and private label offerings - BofA Securities
** HSIC is positioned for long-term success with "best-in-class portfolio in dental", with above-market exposure to DSO customers - brokerage
** Six of 15 brokerages rate the stock "buy" or higher, 7 "hold" and 2 "sell"; median PT is $75 - data compiled by LSEG
** HSIC fell 8.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.